Germany's Merck KGaA to Acquire US Contract Manufacturer Exelead.

MANews-(C)2009-2022

Germany-based science and technology company Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire US-based biopharmaceutical contract development and manufacturing organization Exelead for approximately USD 780m in cash, the company said.

Exelead specializes in complex injectable formulations, including Lipid Nanoparticle based drug delivery technology which is key in mRNA therapeutics for use in COVID-19 and many other indications.

The acquisition of Exelead is another milestone to accelerate innovation in the Process Solutions business unit of Merck KGaA, Darmstadt, Germany, one of the company's three growth engines, through targeted smaller to medium-sized acquisitions with high impact.

It follows the company's acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA CDMO, that was announced at the beginning of 2021.

The transaction enhances the company's more than 20 years' experience in producing lipids, one of the critical components for the formulation of mRNA therapeutics...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT